DUBOIS LUPUS ERYTHEMATOSUS AND RELATED SYNDROMES WITH ACCESS CODE 10ED (PB 2025). Dieser Artikel ist nicht verfügbar.DUBOIS LUPUS ERYTHEMATOSUS AND RELATED SYNDROMES WITH ACCESS CODE 10ED (PB 2025)

**Selected for 2025 Doody’s Core Titles® in Rheumatology**

For more than 50 years, Dubois’ Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical management, the 10th edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a logical, clearly written, user-friendly manner. It’s an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes.

• Provides complete clinical coverage of every aspect of cutaneous and systemic lupus erythematosus, including definitions, pathogenesis, autoantibodies, clinical and laboratory features, management, prognosis, and patient education.
• Includes significant new content throughout: a new chapter on the endocrine system and hormones; newly distinct chapters on the heart and lung; new content on social disparities in lupus, clinical presentation of nephritis, and pulmonary hypertension; a new concluding chapter on future directions in the field; new basic science coverage of the microbiome, autoinflammatory, and monogenic lupus; and new coverage of diversity, inclusion, gender, compliance, and adherence.
• Offers a fresh perspective from two new associate editors and many new authors with representation from 30 countries.
• Contains an up-to-date overview of significant advances in cellular, molecular, and genetic technologies, including genetic advancements in identifying at-risk patients.
• Discusses the clinical management of related disorders such as Sjogren’s syndrome, scleroderma, polymyositis, and antiphospholipid syndrome (APS).
• Presents the knowledge and expertise of international contributors to provide new global perspectives on manifestations, diagnosis, and treatment.
• Features a vibrant, full-color format, with graphs, algorithms, differential diagnosis comparisons, new and improved figures, and schematic diagrams throughout.
• An eBook version is included with purchase. The eBook allows you to access all of the text, figures, and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date.

Daniel J Wallace MD, FACP, MACR is a board-certified internist and rheumatologist. A Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA, he is the Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai Medical Center, where he also serves on the Board of Governors. Dr. Wallace has authored nearly 450 peer reviewed manuscripts, 30 book chapters, eight textbooks (on lupus, osteoarthritis, Sjogren’s syndrome and fibromyalgia) and his practice includes caring for 2,000 lupus patients, the largest lupus cohort in the United States. Dr Wallace is co-chair of the Lupus Industry Council of the Lupus Research Alliance, past chair of the Lupus Foundation of America, and has served on the Board of Directors of the United Scleroderma Foundation and the Medical Advisory Board of the Sjogren’s Syndrome Foundation. He has been Chief of Rheumatology at the City of Hope and Cedars-Sinai Medical Center, and chairman of the Research and Education Foundation of the American College of Rheumatology.

Dr. Hahn received her MD from the Johns Hopkins University School of Medicine, where she later trained in Rheumatology. She trained in internal medicine at Washington University in St. Louis. Dr. Hahn heads research groups that do basic studies in the immune abnormalities that cause systemic lupus erythematosus (SLE) and is developing interventions that help restore the immune response to normal. She also heads a group that studies clinical problems in patients with SLE, including accelerated atherosclerosis and potential new therapies (clinical trials). In addition, Dr. Hahn provides clinical consultations for patients with rheumatic diseases, particularly SLE. She also teaches Rheumatology and heads the administration of the Division of Rheumatology, which has 25 full-time faculty, 8 fellows and several undergraduate students, medical students, PhD students, postdoctoral trainees, and an administrative staff.